BioNTech is trading down 4.5% at $111.33 amid a broader risk-off tone, with the Nasdaq Composite down 0.60%.
- No new company-specific announcement explaining the August 24, 2026 decline was identified.
- The stock is pulling back after closing at $116.57 on August 21, following a sharp multi-session rally tied to positive Moderna-Merck cancer-vaccine results.
- That catalyst lifted BioNTech alongside other vaccine developers but does not directly explain today’s decline.